Study Of The Effects Of A New Antidepressant Therapy In Patients With Major Depressive Disorder (MDD)

• Status: Completed
• Trial end date: 2006-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to assess the efficacy, safety and tolerability of GW679769 patients with Major depressive Disorder (MDD).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: GlaxoSmithKline
• Treatments: Casopitant

Criteria

Inclusion criteria:

• Primary diagnosis of Major depressive Disorder as defined in DSM-IV.

• Capable of giving informed consent and willing to comply with the study requirements.

• Women of childbearing potential must agree to one of a number of defined acceptable methods of birth control.

Exclusion Criteria:

• Primary diagnosis within the past 6 months of another Axis 1 disorder such as an anxiety disorder.

• Use of medications for a psychiatric condition including herbals in the past 2-12 weeks according to medication type.

• Subjects who, in the investigator's judgement, pose a current, serious suicidal or homicidal risk or have made a suicide attempt within the past 6 months.

• Subjects who currently meet or who met within 6 months prior to screening DSM-IV criteria for substance abuse or subjects who currently meet or who met within 6 months prior to screening DSM-IV criteria for substance dependence (other than nicotine).

• Significantly abnormal blood or urine laboratory tests or electrocardiogram (ECG).